Why the study?
Anthracyclines cause severe cardiotoxicity and are metabolically reduced to hydroxy metabolites implicated in this toxicity, prompting investigation into their cellular disposition and effects.
Population
Isolated rat neonatal cardiomyocytes
Comparison
Daunorubicin vs daunorubicinol, with or without dexrazoxane
Design
In vitro cellular study
Authors
Loading...
Daunorubicin drives cardiomyocyte cytotoxicity more than daunorubicinol in vitro; leaves open metabolite targeting for clinical anthracycline cardiotoxicity prevention.
Daunorubicin is the primary driver of cardiomyocyte cytotoxicity rather than its hydroxy metabolite, challenging the notion that the metabolite is a significant toxic reservoir.
Applová et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: